[HIPEC in ovarian cancer: What should we expect?]

Bull Cancer. 2019 Nov;106(11):1023-1028. doi: 10.1016/j.bulcan.2019.04.003. Epub 2019 May 22.
[Article in French]


The results of PRODIGE 7 study demonstrate that the use of HIPEC is not beneficial for patients in the treatment of colorectal carcinomatosis. Nevertheless, a recent study published in NewEnglandJournalofMedicine showed that hyperthermic intraperitoneal chemotherapy (HIPEC) increased overall survival for patients with ovarian peritoneal carcinomatosis. Although, the emergence of targeted therapies (anti-angiogenic agents, PARP-inhibitors, anti-PDL1) results in new standards of treatment in first line or recurrence disease. In this general context, what is the potential interest of HIPEC for the treatment of ovarian carcinoma?

Keywords: CHIP; Carcinomatosis; Carcinose; HIPEC; Ovaire; Ovarian.

Publication types

  • Review

MeSH terms

  • Female
  • Humans
  • Hyperthermia, Induced*
  • Ovarian Neoplasms / complications
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / therapy*
  • Peritoneal Neoplasms / etiology
  • Peritoneal Neoplasms / therapy*
  • Prospective Studies